Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection
Status:
Completed
Trial end date:
2016-12-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of treatment using a
combination of drugs (entecavir and pegylated interferon) in children ages 3-<18 years old
with immunotolerant chronic hepatitis B.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)